Daniella Magen

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +10

Mutations in DHDPSL Are Responsible For Primary Hyperoxaluria Type III

Ruth Belostotsky, Eric Seboun, Gregory H. Idelson et al. · The American Journal of Human Genetics · 2010 · 231 citations · Full text

Life Sciences, Genetics, Molecular Genetics +4

Mitochondrial Hsp60 Chaperonopathy Causes an Autosomal-Recessive Neurodegenerative Disorder Linked to Brain Hypomyelination and Leukodystrophy

Daniella Magen, Costa Georgopoulos, Peter Bross et al. · The American Journal of Human Genetics · 2008 · 211 citations · Full text

Life Sciences, Neurobiology, Neuroscience +15

A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria

Daniella Magen, Eli Sprecher, Israel Zelikovic et al. · Kidney International · 2004 · 116 citations · Full text

Medicine, Genetics, Molecular Genetics +10

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial

Mini Michael, Jaap W. Groothoff, Hadas Shasha‐Lavsky et al. · American Journal of Kidney Diseases · 2022 · 81 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11